NCT06349408 - IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

250

Participants

Timeline

Start Date

January 10, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Locally Advanced Solid Tumor

Interventions

DRUG

IBI3001

"The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the study.~IBI3001 is proposed to be administered by intravenous infusion (IV)"

Trial Locations (5)

2500

RECRUITING

Wollongong Public, Wollongong

5000

RECRUITING

Cancer Research SA, Adelaide

100853

NOT_YET_RECRUITING

Chinese PLA General Hospital, Beijing

200120

NOT_YET_RECRUITING

Shanghai East Hospital, Shanghai

310003

NOT_YET_RECRUITING

The First Affiliated Hospital of zhejiang University School of Medicine, Hangzhou

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY